mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE and an ADC linker (peptide Val-Cit- PAB) composition[1].
References:
[1]. Moquist, et al. Preparation of drug conjugates of IgG1 antibodies with self-stabilizing linkers having improved psiochemical properties for treating cancers and autoimmune diseases. World Intellectual Property Organization, WO2018031690 A1. 2018-02-15.
















